January 18, 2019 06:30 AM EST

Immunomedics must endure another delay as FDA rejects cancer drug citing manufacturing issues

We all like to root for the underdog. Following an arid spell stretching over three decades that in 2017 led to the ouster of …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Im­munomedics must en­dure an­oth­er de­lay as FDA re­jects can­cer drug cit­ing man­u­fac­tur­ing is­sues